Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17204261 | 0.85 | CTBP2 (0.48) | CTBP2ALDH1A1MAPTKDM4EMTNR1A | |
| SCHEMBL17204262 | 0.85 | CTBP2 (0.48) | CTBP2ALDH1A1MAPTKDM4EMTNR1A | |
| SCHEMBL30172840 | 0.85 | CTBP2 (0.48) | CTBP2ALDH1A1MAPTKDM4EMTNR1A | |
| SCHEMBL15093697 | 0.85 | CTBP2 (0.46) | CTBP2ALDH1A1MAPTKDM4ERAB9A | |
| SCHEMBL15093699 | 0.85 | CTBP2 (0.46) | CTBP2ALDH1A1MAPTKDM4ERAB9A | |
| SCHEMBL3179495 | 0.84 | CTBP2 (0.47) | CTBP2ALDH1A1MAPTKDM4ECYP1A2 | |
| SCHEMBL2432376 | 0.83 | KMT2A (0.51) | CTBP2ALDH1A1RAB9AHPGDTDP1 | |
| SCHEMBL2432378 | 0.83 | KMT2A (0.51) | CTBP2ALDH1A1RAB9AHPGDTDP1 | |
| SCHEMBL15093547 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL15093309 | 0.82 | KMT2A (0.47) | CTBP2ALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| WO-2025119254-A1 | METHOD FOR PREPARING DIHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-12 | — | — | WO | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | CTBP2 2523/4885ALDH1A1 1679/4885MAPT 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.